Co-infusion of basal-bolus insulin and pramlintide in an artificial pancreas
This study will assess the efficacy of pramlintide-insulin co-infusion on improving day-and-night blood sugar levels in individuals with type I diabetes compared to insulin on its own. Pramlintide is a synthetic analog of amylin. Amylin is a hormone that is usually secreted from the pancreas with insulin in response to food to help control blood sugar, but is not produce in patients with type 1 diabetes.
Safety and efficacy of closed-loop system (artificial pancreas) compared to conventional pump therapy in regulating glucose levels after a missed meal-time bolus in adolescents with type 1 diabetes.
A primary factor for poor glucose control in adolescents is the omission of insulin boluses at mealtimes. Accordingly, this study will assess the safety and efficacy of closed-loop insulin delivery with and without a meal detection module compared to conventional pump therapy in regulating post-prandial glycaemia after omission of a meal bolus in adolescents with type 1 diabetes.
Alleviating carbohydrate-counting burden in type 1 diabetes using artificial pancreas and sodium glucose-linked transporter 2 inhibition (SGLT2i)
Alleviating the burden of carbohydrate counting is of fundamental importance as accurate carbohydrate counting is a challenging task for many patients with type I diabetes. Inhibition of Sodium Glucose-Linked Transporter 2 has been shown to be effective in improving glucose control in type 2 diabetes. This study aims to determine if adjunctive use of SGLT2 inhibition with the single and dual-hormone artificial pancreas can alleviate the carbohydrate-counting burden in adults with type I diabetes without degrading postprandial glucose control.
The learning algorithm
The objective of this project is to develop a learning algorithm that optimizes the performance of the artificial pancreas over time, through optimizing patient's basal rates and insulin-to-carbohydrate ratios, ultimately resulting in tighter glucose control in both closed-loop or open-loop modes. The learning algorithm will be tested using computer simulations and clinical trials in children and adults with type 1 diabetes.
Triple-hormone, fully automated artificial pancreas system for type 1 diabetes
This project involves developing a triple-hormone, fully automated, artificial pancreas system for people with type 1 diabetes. This new artificial pancreas would continuously monitor a person’s blood glucose levels and automatically deliver either insulin, pramlintide, or glucagon as needed to regulate and maintain a safe and normal blood glucose level. Such a system would require no input from the person wearing it, meaning no carbohydrate counting and no insulin adjustments. Ultimately, it would act as a healthy pancreas and mean fewer complications for people with type 1 diabetes.